Details

Autor(en) / Beteiligte

• Arikoglu, Tugba
• Kont, Aylin Ozhan
• Demirhan, Ali
• Yuksek, Burcu Caglar
• Tokmeci, Nazan
• Kuyucu, Semanur

Titel

Risk stratification in beta-lactam allergy

Ist Teil von

• Current treatment options in allergy, 2021-12, Vol.8 (4), p.285-297

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Purpose of Review Beta-lactams (BLs) are among the most commonly prescribed and effective antibiotics. Given the fact that overdiagnosis of penicillin allergy constitutes a major public health problem by increasing health costs and contributing to overall antibiotic resistance, removing BL allergy label is crucial. Recent Findings Delabeling penicillin allergy as an essential component of antimicrobial stewardship is a hot topic. Despite several clinical risk factors and genetic characteristics proposed to predict BL allergy, it is still unclear what exactly constitutes a risk. Recently, a great deal of interest has been focused in the design of risk stratification and implementing pathways in order to classify the risk based on the clinical history. Appropriate risk stratification is critical to ensure that high-risk patients are referred to allergy specialist for further diagnostic assessment, whereas direct drug provocation tests can be safely employed in low-risk patients. Summary Many patients labeled as allergic to BLs are able to tolerate these drugs. The huge burden of penicillin allergy can be tackled by integrating risk-based and traditional testing strategies into antibiotic stewardship programs. Promising potential methods to accurately assess BL allergy risk will require collaborative multimodal approaches including risk stratification pathways with validated tools.